ArticleJournal of gastroenterology2021
CCL19 enhances CD8
Article in Journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Integrated mRNA-miRNA Transcriptome Analysis Reveals the Molecular Mechanism of Tibetan Sheep Rumen Epithelium Adaptation to High Altitude.Animals : an open access journal from MDPI · 2026Article
- A genomic and transcriptomic integration study of CCL19-driven macrophage-immune crosstalk in chronic hepatitis B.Clinical and experimental medicine · 2026Article
- Uncovering potentially targetable genes in liver fibrosis via bioinformatics and experimental validation.Scientific reports · 2026Article
- Inhibition of LSD1 enhances T cells anti-tumor immunity by promoting TNFSF14 expression in gastric cancer.Molecular and cellular biochemistry · 2026Article
- Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma.Materials today. Bio · 2025Article
- The expression and prognostic value of CCL19 in breast cancer.Discover oncology · 2025Article
- Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.Biomedicines · 2025Article
- Activin A promoted the anti-tumor effect of ActRIIACancer medicine · 2025Article
- Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma.Journal for immunotherapy of cancer · 2024Article
- Causal Relationships Between Circulating Inflammatory Proteins and Obstructive Sleep Apnea: A Bidirectional Mendelian Randomization Study.Nature and science of sleep · 2024Article
- Associations of inflammatory cytokines with palmoplantar pustulosis: a bidirectional Mendelian randomization study.Frontiers in medicine · 2024Article
- CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.Aging · 2023Article
- Genome-wide analysis of long noncoding RNA profiles in pseudorabies-virus-infected PK15 cells.Archives of virology · 2023Article
- A two-sample Mendelian randomization analysis: causal association between chemokines and pan-carcinoma.Frontiers in genetics · 2023Article
- The role of regulatory T cells and follicular T helper cells in HBV infection.Frontiers in immunology · 2023Review
- Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity.Frontiers in immunology · 2023Review
- Does CCL19 act as a double-edged sword in cancer development?Clinical and experimental immunology · 2022Review
- Integrated analysis of immune parameters, miRNA-mRNA interaction, and immune genes expression in the liver of rainbow trout following infectious hematopoietic necrosis virus infection.Frontiers in immunology · 2022Article
- Infectious bursal disease virus replication is inhibited by avain T cell chemoattractant chemokine CCL19.Frontiers in microbiology · 2022Article
- Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemokine (C-C motif) ligand 19 (CCL19) is a leukocyte chemoattractant that plays a crucial role in cell trafficking and leukocyte activation. Dysfunctional CD8
methodsWe assessed the effects of CCL19 on the activation of PBMCs in patients with HBV infection. We also examined how CCL19 influences HBV clearance and modulates HBV-responsive T cells in a mouse model of chronic hepatitis B (CHB). In addition, C-C chemokine-receptor type 7 (CCR7) knockdown mice were used to elucidate the underlying mechanism of CCL19/CCR7 axis-induced immune activation.
resultsFrom in vitro experiments, we found that CCL19 enhanced the frequencies of Ag-responsive IFN-γ
conclusionsFindings in this study provide insights into how CCL19/CCR7 axis modulates the host immune system, which may promote the development of immunotherapeutic strategies for HBV treatment by overcoming T-cell tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.